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P450 RhF from Rhodococcus sp. NCIMB 9784 is the
first example of a new class of cytochrome P450 in which
electrons are supplied by a novel, FMN- and Fe/S-con-
taining, reductase partner in a fused arrangement. We
have previously cloned the gene encoding the enzyme
and shown it to comprise an N-terminal P450 domain
fused to a reductase domain that displays similarity to
the phthalate family of oxygenase reductase proteins. A
reductase of this type had never previously been re-
ported to interact with a cytochrome P450. In this report
we describe the purification and partial characteriza-
tion of P450 RhF. We show that the enzyme is self-
sufficient in catalyzing the O-dealkylation of 7-ethoxy-
coumarin. The P450 RhF catalyzed O-dealkylation of
7-ethoxycoumarin is inhibited by several compounds
that are known inhibitors of cytochrome P450. Pre-
steady state kinetic analysis indicates that P450 RhF
shows a 500-fold preference for NAPDH over NADH in
terms of Kd value (6.6 M versus 3.7 mM, respectively).
Potentiometric studies show reduction potentials of
243 mV for the two-electron reduction of the FMN and
423 mV for the heme (in the absence of substrate).
Cytochrome P450 is a superfamily of monooxygenase en-
zymes with diverse catalytic activities. These have been found
in all three phylogenetic domains of life, including many higher
animal tissues. The primary chemical reaction catalyzed by
these monooxygenases is the two-electron activation of molec-
ular dioxygen, whereby one oxygen atom is inserted into the
substrate with concomitant reduction of the second atom to
water. NAD(P)H provides the required electron equivalents via
a number of different redox partners (1).
Depending on the nature of the redox partner, P450 enzymes
generally fall into two broad classes. Class I enzymes are three-
component systems comprising an NAD(P)H-binding flavopro-
tein reductase, a small iron-sulfur protein, and the P450. These
enzymes are found in the mitochondrial membranes of eu-
karyotes and in most bacteria. Class II enzymes are two-com-
ponent systems comprising an FAD- and FMN-containing
NADPH reductase (in which FAD and FMN are in an equimo-
lar ratio) and the P450. This type of P450 is found almost
exclusively in eukaryotes in association with the endoplasmic
reticulum, where they play a major role in the oxidative me-
tabolism of a wide spectrum of substrates including xenobiot-
ics, endogenous fatty acids, steroids, leukotrienes, prostaglan-
dins, and vitamins.
There are, however, examples of cytochrome P450 that can-
not readily be defined as a member of either of these two
classes. P450 BM3 (CYP102A1) from Bacillus megaterium,
which oxidizes long chain fatty acids, comprises a diflavin
reductase fused to the P450 to form a catalytically self-suffi-
cient single polypeptide enzyme (2, 3). P450 BM3 has been
likened to a fused eukaryotic class II enzyme. However, since
its primary structural organization is quite distinct from the
class II enzymes, P450 BM3 is regarded as the first example of
a new, self-sufficient, class of P450 enzyme. Two further exam-
ples of P450 enzymes of this type (CYP102A2 and CYP102A3)
from Bacillus subtilis were identified as a result of a whole
genome sequencing project (4). A BM3-like P450 from the ac-
tinomycete Actinosynnema pretiosum, which is thought to be
involved in the biosynthesis of the polyketide antitumor agent
ansamitocin, has also been described (5). Two membrane-
bound eukaryotic counterparts of P450 BM3 have been cloned
from Fusarium oxysporum (6) and Fusarium verticillioides (7).
Recently, a search against a data base of unfinished genome
sequencing projects identified three more examples from Ba-
cillus anthracis (Ames strain), Bacillus cereus, and the -pro-
teobacterium Ralstonia metallidurans (8).
During a PCR-based screen for new P450 activities from
actinomycetes, we cloned a novel P450 gene from Rhodococcus
sp. NCIMB 9784 (previously classified as Corynebacterium sp.
Strain T1), which was of unique primary structural organiza-
tion (9). Surprisingly, an analysis of the gene revealed that it
encoded a heme domain fused to a reductase displaying con-
vincing similarity to the phthalate family of dioxygenase re-
ductases. We named the enzyme P450 RhF to reflect both its
origin and the fused nature of the gene product. Despite the
fact that proteins homologous to the C-terminal reductase por-
tion of P450 RhF have been found in a diverse range of organ-
isms, this was the first time an oxidoreductase of this type had
been implicated in partnering a P450 enzyme. The N-terminal
heme portion of the enzyme displays striking similarity to the
thiocarbamate-inducible P450 from Rhodococcus erythropolis
NI86/21 (ThcB), a class I enzyme of the CYP116 family (10).
Working independently, De Mot and Parret (8) identified four
putative homologues to P450 RhF from three pathogenic Burk-
holderia species and the heavy metal-resistant bacterium
R. metallidurans by analyzing unfinished genomes with the
ThcB sequence.
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We have previously shown that a recombinant strain of
Escherichia coli expressing the gene for P450 RhF was able to
dealkylate 7-ethoxycoumarin, whereas the same strain lacking
this gene was unable to do so. However, in these whole cell
studies we could not definitively demonstrate that the enzyme
was catalytically self-sufficient due to the possible involvement
of endogenous electron transfer proteins. In this report we
describe the isolation and partial characterization of recombi-
nant P450 RhF.
EXPERIMENTAL PROCEDURES
Enzymes and Chemicals—All chemicals were purchased from Sigma-
Aldrich. Biotinylated thrombin was supplied by Novagen (Madison,
WI). A protease inhibitor mixture containing 4-(2-aminoethyl)benzene-
sulfonyl fluoride, bestatin, pepstatin A, trans-epoxysuccinyl-L-leucyl-
amido(4-guanido)butane, and N-(-rhamnopyranosyloxyhydroxyphos-
phinyl)-Leu-Trp-(phosphoramidon) was supplied by Sigma-Aldrich.
Restriction endonucleases, T4 DNA ligase, Vent DNA polymerase, and
calf intestinal alkaline phosphatase were from New England Biolabs
(Beverly, MA).
Maintenance and Growth of Microorganisms—Rhodococcus sp.
NCIMB 9784 was obtained from the National Culture of Industrial and
Marine Bacteria (Aberdeen, UK). The strain was maintained on nutri-
ent agar slopes at room temperature, and grown in Luria-Bertani (LB)
medium (11) at 30 °C in baffled flasks. E. coli XL2-Blue MRF’ ultra-
competent cells were purchased from Stratagene (La Jolla, CA) and
grown in LB medium at 37 °C. E. coli BL21(DE3) cells were obtained
from Invitrogen (Groningen, The Netherlands) and grown at 30 °C in
LB medium unless stated otherwise. Ampicillin was used at 100 g/ml
when required for selection of plasmid on both liquid and solid medium.
pET14b used in the expression studies was obtained from Novagen.
DNA Manipulations—Standard DNA procedures were used through-
out (11). Total DNA was prepared from Rhodococcus sp. NCIMB 9784
as described previously (12). The full-length gene encoding P450 RhF
was cloned into pET14b for expression to give a fusion protein with a
20-residue N-terminal prepeptide, which includes a His6 tag and a
thrombin cleavage site. The P450 RhF gene was amplified by PCR and
cloned into the expression vector. The forward and reverse primers for
the amplification were 5-CGGTGTCCATATGAGTGCATCAGTTCCG-
GCG-3 and 5-AGGTTGATCATTCAGAGTCGCAGGGCCAGCC-3, re-
spectively. The NdeI and BclI restriction endonuclease sites used for the
subsequent cloning of the PCR product are underlined.
The PCR consisted of 30 cycles, with denaturation at 94 °C for 1 min
30 s, annealing at 60 °C for 45 s and extension for 2 min 30 s at 72 °C.
The initial denaturation step was at 95 °C for 2 min. The PCR mix
included Vent DNA polymerase (New England Biolabs, MS), 10 mM
Tris-HCl (pH 9.0 at room temperature), 50 mM KCl, 1.5 mM MgCl2, 200
M of each deoxynucleoside triphosphate, 40 pM of each primer, 10%
(v/v) dimethyl sulfoxide, and 50 ng of Rhodococcus sp. NCIMB 9784
total genomic DNA as template in a reaction volume of 50 l.
The PCR product was isolated and digested with NdeI and BclI
restriction endonucleases. The digested DNA was purified and cloned
into the NdeI and BamHI sites of the pET14b vector to give the final
expression construct (pAG04). Plasmid construction was performed in
E. coli XL1-Blue MRF. The insert DNA was sequenced to ensure no
mistakes had been introduced during the amplification process. pAG04
was then transformed into the expression strain E. coli BL21(DE3).
Production of His6-P450 RhF—E. coli BL21(DE3) containing the
expression construct was grown in LB medium containing 100 g/ml
ampicillin at 30 °C. We had previously demonstrated that a non-tagged
version of P450 RhF was synthesized in a largely insoluble form when
the culture temperature was elevated to 37 °C (9). After induction with
1 mM IPTG1 at an optical density (OD600) of 0.8, growth was continued
for up to 4 h before harvesting. Aliquots were withdrawn at regular
time points. Expression was assessed by comparing the banding pattern
obtained by SDS-PAGE analysis of whole cell extracts with that of a
negative control (i.e. E. coli BL21(DE3)pET14b). The solubility of the
protein was assessed by a standard procedure (11).
Although expression was found to be constitutive, we followed the
standard induction protocol using IPTG for protein purification studies.
Typically a starter culture (100 ml of LB containing 100 g/ml ampi-
cillin) was grown to an optical density of 0.8–1.0 from a single colony
(16 h growth at 30 °C) using a baffled shake flask. This was then used
to inoculate 10 liters of LB medium (containing 100 g/ml ampicillin) in
a fermentor (Bioflo 4500, New Brunswick Scientific, Edison, NJ). When
the OD600 reached 0.4 (after 4 h growth) expression of the recombi-
nant gene was induced by adding 1 mM IPTG. Cells were harvested 3 h
after IPTG induction and stored at 20 °C. Typically, using this proto-
col, we obtained about 20–25 g of cell paste from 10 liters of broth.
Protein Purification—Approximately 20 g of cell paste was sus-
pended in 20 ml of ice-cold buffer A (25 mM Tris-HCl, pH 7.8, 300 mM
NaCl, 10% (v/v) glycerol) containing 0.1 mM phenylmethylsulfonyl flu-
oride, and 200 l of protease inhibitor mixture (Sigma-Aldrich). The
cells were disrupted by sonication using a Soniprep 150 sonicator
(Sanyo, Tokyo, Japan) fitted with a 9-mm diameter probe. The cell
suspension was split into two equal volumes for disruption and each
aliquot was kept on ice and sonicated with a 15 s burst followed by a 45 s
interval. This process was repeated 12 times. The resulting cell extract
was centrifuged at 48,000  g for 20 min at 4 °C. The cell-free extract
was carefully removed and filtered through a 0.45-micron filter unit.
The clarified extract was then loaded onto a 5-ml Nickel HiTrap column
(Amersham Biosciences), equilibrated in buffer A at a flow rate of 1
ml/min. Column chromatography was performed at 4 °C. The column
was then extensively washed with buffer A (12 column volumes) to
remove unbound material. The majority of contaminating proteins were
then removed by washing with 30 mM imidazole in buffer A (10 column
volumes) before elution of the recombinant His-tagged P450RhF by 300
mM imidazole in buffer A.
The buffer was exchanged using a PD-10 desalting column (Amer-
sham Biosciences) which was equilibrated in Buffer B (50 mM Tris-HCl,
pH 7.8, 10% (v/v) glycerol, 0.5 mM dithiothreitol) at 4 °C. The small
amount of contaminating protein was removed by anion exchange chro-
matography. The protein sample (7.0 ml) was loaded onto a Re-
source-Q column (6 ml) (Amersham Biosciences) at a flow rate of 3
ml/min. The column was then washed with two column volumes of
Buffer B. Protein was eluted using a linear gradient of 0–1.0 M NaCl in
buffer B over 20 column volumes. P450 RhF was eluted in 250 mM
NaCl.
The sample volume (4 ml) was reduced to 1 ml using a spin
concentrator with a 30 kDa cut-off membrane (Sartorius, Goettingen,
Germany). Glycerol was added to a final concentration of 50% (v/v) and
the sample stored at 20 °C.
Removal of the N-terminal His Tag—The N-terminal His tag was
removed using biotinylated thrombin. Typically, 1.0 unit of thrombin
was incubated with 200 g of P450 RhF at 22 °C for 90 min. Biotiny-
lated thrombin was subsequently removed using streptavidin agarose.
Protein was then recovered by spin-filtration. The extent of cleavage
was determined by both Western blot analysis using an anti-His tag
antibody and by mass spectrometry.
Mass Spectrometry—Mass spectrometry of the intact recombinant
P450 RhF was performed by MALDI-TOF using a Voyager DE STR
instrument (Applied Biosystems, Foster City, CA). Protein samples
were diluted in 0.1% trifluoroacetic acid to0.05 mg/ml and mixed with
an equal volume of matrix (saturated solution of sinapinic acid in 50%
acetonitrile, 0.1% trifluoroacteic acid) on a stainless steel surface. The
samples were air dried at room temperature to crystallize. The machine
was operated in positive ion mode and calibrated with conalbumin and
bovine serum albumin.
Western Blotting—Protein samples were resolved on 10–20% SDS-
PAGE gels and electroblotted onto a nitrocellulose membrane (Hybond
ECL, Amersham Biosciences) using a Bio-Rad transblot cell at a constant
current of 150 mA for 90 min. After blocking in 5% (w/v) dried milk
powder the blot was subjected to immunodetection using mouse mono-
clonal anti-polyhistidine antibody peroxidase conjugate (Sigma-Aldrich)
diluted 1:1000. Following extensive washing the blot was developed using
3,3-diaminobenzidine in urea/hydrogen peroxide (FAST DAB tablets,
Sigma-Aldrich) according to the manufacturers’ guidelines.
Spectroscopic Analysis—The homogeneity of the protein preparation
was assessed by SDS-PAGE using a 10–20% gradient gel. The spectral
properties (ratio of P450-specific absorption at 420 nm compared with
protein-specific absorption at 280 nm) were also measured. The cyto-
chrome P450 concentration was determined by the method described in
the literature (13), using an extinction coefficient of 450–490  91 mM
1
cm1.
Absorption spectra of P450 RhF in the UV-visible region were re-
corded with a Shimadzu UV-2101PC scanning spectrophotometer (Shi-
madzu, Duisburg, Germany) using a 1-cm pathlength quartz cell. Spec-
tra were recorded using 0.1–0.2 M P450 RhF in phosphate buffer (50
mM potassium phosphate buffer, pH 7.8, 10% (v/v) glycerol). Spectra of
the reduced enzyme were recorded after the addition of a few grains of
1 The abbreviations used are: IPTG, isopropyl--D-thiogalactopyrano-
side; MALDI-TOF, matrix-assisted laser desorption ionization time-of-
flight; OTTLE, optically transparent thin layer electrochemical.
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sodium dithionite. Reduced enzyme was reacted with CO by gently
bubbling CO gas into a solution of reduced P450 RhF.
Presteady State Kinetics—Presteady state measurements on the re-
duction of P450 RhF by either NADPH or NADH were performed at
25 °C using an Applied Photophysics stopped-flow spectrophotometer
(SX.17MV) contained within an anaerobic glove box (Belle Technology,
Portesham, UK; [O2]  5 ppm) using either single-wavelength or diode-
array detectors. Enzyme and nucleotide solutions were made up in 50
mM Tris-HCl, pH 7.5, 100 mM NaCl, 10% (v/v) glycerol. Concentrations
were checked spectrophotometrically before use. FMN reductions were
recorded at 462 nm, and the resultant traces analyzed using Origin 7
software (Microcal, Northampton, MA).
Steady State Kinetics—The P450 RhF catalyzed formation of 7-hy-
droxycoumarin from 7-ethoxycoumarin was monitored directly by fluo-
rescence spectrophotometry in a 96-well plate format. A microtiter plate
reader (SPECTRAmax GEMINIXS, Molecular Devices, Sunnyvale, CA)
was set up as follows: excitation wavelength, 397 nm; emission wave-
length, 466 nm; cut off wavelength, 420 nm; temperature, 30 °C. Under
these conditions, there was no interference from the substrate 7-ethoxy-
coumarin. A series of eight solutions of 7-ethoxycoumarin (0–2 mM)
were prepared by successive dilutions of a stock solution of 10 mM
7-ethoxycoumarin in Me2SO into 50 mM potassium phosphate buffer,
pH 7.8. The maximum final concentration of Me2SO was 10% (v/v)
Me2SO. From this series, 185 l was transferred into wells of the
96-well plate. 5 l of P450 RhF from a 3.4 M stock solution was added
(0.086 M) into each well and equilibrated for 3 min at room tempera-
ture. The reaction was initiated by addition of 10 l of NAD(P)H
solution from a freshly prepared stock (10 mM) using an 8-channel
pipette. The plate was then immediately placed into the plate reader.
The plate was shaken for 5 s to ensure thorough mixing, and then
time-based measurements were recorded every 15 s for 10 min. The rate
of formation of 7-hydroxycoumarin was calculated using an extinction-
emission coefficient of   1502 mM1, which was determined using
7-hydroxycoumarin standards.
For the inhibition studies, each inhibitor (either 5 or 10 mM) was
pre-incubated with the assay mix (minus cofactor) for 5 min prior to
initiating the reaction with NADPH. A negative control was also in-
cluded in which no inhibitor was added. Steady state consumption of
NADPH or NADH by P450 RhF could be measured using K3[Fe(CN)6]
as an artificial electron acceptor. In a typical reaction, 1 mM (a satu-
rating concentration) of K3[Fe(CN)6] in phosphate buffer was incubated
with 5–6 nM of P450 RhF for 3 min and the reaction was initiated by
addition of either NADH or NADPH at different concentrations (0–60
M). The reaction was monitored at 340 nm (30 °C) for 10 min using a
microtiter plate reader (VERSAmax, Molecular Devices).
Optically Transparent Thin Layer Electrochemical (OTTLE) Poten-
tiometry—Spectroelectrochemical analysis of P450 RhF was conducted
in an OTTLE cell constructed from a modified quartz EPR cell with a
0.3-mm path length, containing a Pt/Rh (95/5) gauze working electrode
(wire diameter 0.06 mm, mesh size 1024 cm1), a platinum wire counter
electrode and a Ag/AgCl reference electrode (model MF2052; Bioana-
lytical Systems, West Lafayette, IN). Enzyme samples (0.5 ml  100–
200 M) were eluted through a G25 column pre-equilibrated with 0.1 M
Tris-HCl, pH 7.5, 0.5 M KCl in an anaerobic glove box. The following
mediators: pyocyanine (10 M), 2-hydroxy-1,4-napthoquinone (20 M),
FMN (5 M), benzyl viologen (10 M), and methyl viologen (10 M) were
then added. Spectroelectrochemical titrations were performed at 25 
2 °C using an Autolab PGSTAT10 potentiostat and a Cary 50 UV/vis
spectrophotometer. The potential of the working electrode was de-
creased in 30 mV steps until the enzyme was fully reduced and in-
creased stepwise until reoxidation was complete. After each step the
current and UV/vis absorption spectrum were monitored until no fur-
ther change occurred. This equilibration process typically lasted 15
min. Absorbance changes at 418 nm (heme) and 462 nm (FMN) were
plotted against the potential of the working electrode and analyzed
simultaneously using the Nernst equation. The Ag/AgCl reference elec-
trode employed in the OTTLE cell was calibrated against indigotrisul-
fonic acid (Em 99 mV versus SHE) and FMN (Em 220 mV versus
SHE) in the same buffer conditions. All electrode potentials were cor-
rected accordingly by 205  2 mV relative to the standard hydrogen
electrode.
RESULTS
Recombinant Expression—The expression construct (pAG04)
was introduced into E. coli BL21(DE3), and the resultant cell
extracts analyzed by SDS-PAGE. A band corresponding to the
predicted molecular mass of the recombinant protein was vis-
ible on Coomassie-stained gels of the expression strain, which
was absent from the control strain (E. coli BL21(DE3)pET14b).
The identity of this band was confirmed by Western blot anal-
ysis using an anti-His tag antibody. Although we observed
significant levels of recombinant protein from cell extracts of
the expression strain grown in the absence of IPTG (i.e. leaky
expression), protein purified from these preparations was gen-
erally subject to substantial proteolytic degradation. Subse-
quent analysis of whole cell extracts by Western blotting con-
firmed that much of this proteolysis was occurring in the cell
prior to disruption (data not shown). In order to minimize this
problem, all subsequent protein preparations were derived
from cells grown in a fermentor to a low cell density (OD 0.4),
induced with IPTG, and then harvested shortly afterward (See
“Experimental Procedures”). The level of recombinant P450
RhF peaked at about 3 h after induction (Fig. 1).
His6-P450 RhF was purified using metal ion affinity and
anion-exchange chromatography (Fig. 2). The His tag was then
efficiently removed by treatment with thrombin. Removal of
the tag was confirmed by both Western blot analysis using an
anti-His tag antibody and by mass spectrometry (Fig. 3). We
could detect no evidence of adventitious proteolysis at sites
outside the targeted scissile bond.
Spectrophotometric Characterization—UV-visible absorption
spectroscopy provides the basic technique for the recognition
and characterization of cytochrome P450 enzymes. Recombi-
nant His6-P450 RhF and recombinant P450 RhF lacking the
His tag gave essentially identical UV-visible absorption spectra
that are typical of P450 hemoproteins (14). The oxidized form of
purified P450 RhF displays the general spectral properties of
FIG. 2. SDS-PAGE analysis of Resource Q column chromatog-
raphy during purification of recombinant His6-P450 RhF. Lane
Ni, pooled fractions from HiTrap Nickel column loaded onto Resource Q
column; lanes 23–30 show fractions from anion exchange chromatogra-
phy on Resource Q column. Fractions 24–25 were used for analysis.
Molecular mass markers are shown in lane M.
FIG. 1. SDS-PAGE analysis of whole cell extracts of a culture of
E. coli BL21(DE3)pAG04 following induction with IPTG. The
arrow indicates the position of the recombinant protein. Molecular
mass markers are shown in lane M.
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cytochrome P450 enzymes with the major Soret band located at
424 nm, and the smaller  and  peaks at 574 and 539 nm,
respectively (Fig. 4). Upon reduction with sodium dithionite,
the Soret band shifts to 423 nm and diminishes in intensity.
Subsequent bubbling of CO through the solution of dithionite-
treated P450 RhF resulted in the characteristic shift of the
Soret band to 450 nm. The CO-difference spectrum displays the
prominent peak at 450 nm (Fig. 4, inset). The spectral charac-
teristics of the enzyme remained unchanged after 3 months
storage at 20 °C in 50% (v/v) glycerol. P450 RhF with and
without the His tag display the same spectral properties, sug-
gesting that the presence of these additional residues at the N
terminus does not perturb the heme environment. Interest-
ingly when the His tag was engineered onto the C terminus of
P450 RhF the purified enzyme displayed the same spectral
characteristics but was enzymatically inactive (data not
shown). In this case the His tag may have perturbed the [2Fe-
2S] cluster, thereby interfering with the electron transfer
process.
Nucleotide Preference of P450 RhF—In order to determine
the pyridine-nucleotide preference of P450 RhF, both pre-
steady state and steady state experiments were performed. The
direct reduction of the FMN group was monitored using
stopped-flow spectrophotometry and the resulting plots of kobs
versus nucleotide concentration can be seen in Fig. 5. These
gave rise to values for NADPH of Kd  6.6  0.8 M and klim 
180  5 s1 with the corresponding values for NADH being
Kd  3.7  0.3 mM and klim 111  5 s
1. The P450 RhF
catalyzed steady state oxidation of NAD(P)H using ferricyanide
as an artificial electron acceptor also showed this cofactor pref-
erence. The NADPH-dependent reduction of potassium ferri-
cyanide gave a kcat of 39  1 s
1 and a Km of 6.6  0.4 M
whereas NADH gave a kcat of 16  2 s
1 and a Km of 0.18 
0.04 mM. These results make it clear that P450 RhF has a large
preference for NADPH rather than NADH.
Kinetics of 7-Ethoxycoumarin Dealkylation—P450 RhF cat-
alyzes the O-dealkylation of 7-ethoxycoumarin to form 7-hy-
droxycoumarin. The kinetic results obtained for His6-P450 RhF
were essentially the same as for the recombinant protein in
which the His tag had been removed. The steady state kinetics
of the O-dealkylation of 7-ethoxycoumarin obeyed Michaelis-
Menten kinetics and a typical plot of rate versus substrate
concentration is shown in Fig. 6. Steady state parameters, kcat
FIG. 4. UV-visible absorption spectrum for purified P450 RhF
(0.6 M): oxidized (solid line), dithionite reduced (dashed line),
and CO-bubbled (dotted line) are shown. The difference spectrum
generated by subtracting the spectrum for ferrous P450 RhF from the
ferrous-carbon monoxy form is also shown (inset).
FIG. 3. Analysis of thrombin-treated His6-P450 RhF. Panel A, MALDI-TOF analysis of protein before (bottom) and after (top) treatment with
thrombin. The experimentally determined mass along with the predicted mass in parentheses (based on the sequence data) are highlighted by
arrows for the singly charged species. Panel B, Western blot of His6-P450 RhF before (lane 1) and after (lane 2) thrombin treatment using an
anti-polyhistidine antibody. The same amount of protein (5 g) was loaded in each lane. SDS-PAGE analysis of the samples showed no apparent
differences before and after treatment with thrombin (data not shown).
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and Km were 4.9 0.1 min
1 and 0.22 0.01 mM, respectively.
The fluorescent properties of 7-hydroxycoumarin, which dif-
fer from 7-ethoxycoumarin, allowed us to accurately and di-
rectly determine a low level of substrate turnover without the
need for indirect measurement of NADPH consumption. The
latter method is usually problematic due to both self-oxidation
and the low level of coupling efficiency often associated with
unnatural compounds acting as substrates. Nevertheless we
also analyzed the rate of depletion of NADPH by monitoring
the absorbance at 340 nm (data not shown). By comparing
these results with those obtained from the direct measurement
of product formation we estimate the coupling efficiency is
between 10–15%.
P450 RhF activity against 7-ethoxycoumarin is inhibited by
a number of general P450 inhibitors. The Ki values for three of
these compounds were determined: 4-phenylimidazole, 0.8 
0.1 mM; 1-phenylimidazole, 1.6  0.1 mM; and metyrapone,
2.5 0.3 mM. All compounds inhibited the formation of product
in a competitive fashion. This is illustrated graphically, in Fig.
7, for the inhibition by 1-phenylimidazole.
P450 RhF activity was unaffected by varying the concentra-
tion of salt (NaCl) up to 500 mM. Me2SO was used as a solvent
to dissolve the substrate. We found that the level of Me2SO
could be used up to 25% (v/v) in our reaction mix without
adversely affecting the activity.
Potentiometry—The spectroelectrochemical analysis of P450
RhF was conducted using optically transparent thin layer elec-
trochemical (OTTLE) potentiometry. The results from these
experiments can be seen in Fig. 8. No hysteresis was observed
in any of the potentiometric experiments indicating full equil-
ibration and reversibility during the procedure. The Nernst
curves shown in Fig. 8 show the large separation between the
reduction potentials for the heme and flavin groups. This made
the fitting of the data very straightforward, giving reliable and
accurate values. The two-electron reduction potential for the
FMN group was found to be 243  15 mV (versus NHE). It
was not possible to accurately determine the two one-electron
potentials for the oxidized/semiquinone and semiquinone/re-
duced couples of the FMN although there was evidence for a
small amount of semiquinone formation (seen as a long-wave-
length, 600 nm, absorbance in Fig. 8) during the potentiometric
experiment. The one-electron reduction potential of the heme
group, in the absence of any substrate, was determined to be
423  10 mV (versus NHE).
DISCUSSION
Previously we had reported the cloning of P450 RhF, an
unusual cytochrome P450 in which the heme domain is fused to
a phthalate-family oxygenase reductase (9). The cloning strat-
egy involved a PCR-based screen for P450-like sequence ele-
ments and required no prior knowledge of the target enzyme
substrate specificity. Hence nothing is known about the likely
natural function of P450 RhF, although we are currently in-
vestigating its substrate specificity by screening against a li-
brary of compounds.2 Nevertheless we reported that a recom-
binant strain of E. coli harboring the gene encoding P450 RhF
is able to mediate the O-dealkylation of 7-ethoxycoumarin in
whole cell biotransformation (9). However, the anticipated self-
sufficiency of P450 RhF was not definitively demonstrated in
these experiments since the possibility that endogenous E. coli
redox proteins had supplied reducing equivalents to the recom-
binant protein in vivo could not be eliminated.
In the present study we have purified the recombinant His-
tagged P450 RhF to apparent homogeneity. The catalysis of the
O-dealkylation reaction followed Michaelis-Menten kinetics
and the steady state parameters for the reaction were deter-
mined. Subsequent removal of the His tag by treatment with
thrombin did not affect enzyme activity. We have therefore
demonstrated the ability of the isolated enzyme to mediate
catalysis in the absence of additional redox proteins. P450 RhF
represents the first example of a self-sufficient cytochrome
P450 that does not possess a primary structural organization
akin to that of P450 BM3.
Three general inhibitors of P450 enzymes were found to
inhibit the O-dealkylation reaction and the Ki value for each
was determined. The three inhibitors are pyridine and imidaz-
ole derivatives that are thought to simultaneously bind to the
lipophilic regions of the protein as well as the heme iron in a
reversible manner (14). A double-reciprocal plot of enzyme
kinetics in the presence and absence of inhibitor clearly dem-
onstrated competitive inhibition, which confirms that the O-
dealkylation reaction is indeed catalyzed by P450 RhF at the
heme active site.
Direct measurement of the reduction of the FMN group by
pyridine nucleotides showed that the enzyme displays a
marked preference for NADPH over NADH. This degree of
preference is almost entirely at the level of cofactor binding
since there is only a very small difference (less than 2-fold) in
the rate constant for FMN reduction whereas there is a very
large (500-fold) difference in the dissociation constants. From
sequence alignments and by analogy with the phthalate family
of oxygenase reductase enzymes we had originally predicted
that P450 RhF would be an NADH-dependent enzyme.
Although P450 RhF uses FMN, in all other P450s it is FAD
that receives the reducing equivalents from the pyridine nucle-
otide. In the microsomal P450s and P450 BM3, FMN is used to
shuttle electrons from the FAD to the heme. Potentiometric
analysis of P450 RhF shows that the FMN has a two-electron
2 A. C¸elik, personal communication.
FIG. 5. Saturation curves plotting kobs versus nucleotide con-
centration for the pre-steady state (stopped-flow) reduction of
the FMN in cytochrome P450 RhF by NADPH and NADH (at
25 °C and pH 7.5). The data were fitted to a rectangular hyperbolic
function to give values of Kd and klim. NADPH (): Kd  6.6  0.8 M,
klim  180  5 s
1. NADH (E): Kd  3.7  0.3 mM, klim  111  5 s
1.
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reduction potential of 243  15 mV. This is well poised for
reduction by NADPH which has a reduction potential around
320 mV. A value of 243 mV is not untypical for flavin-
containing reductases and lies between the two-electron reduc-
tion potentials of the FAD and FMN in P450 BM3 which are
around 300 and 200 mV, respectively (15).
The reduction potential for the heme, in the absence of sub-
strate, was found to be 423  10 mV. This is identical, within
experimental error, to the substrate-free heme potential seen
for P450 BM3, reported as 427  4 mV (16). In P450 BM3
(and many other P450s) it has been shown that the binding of
substrate causes a change in the spin state of the heme-iron,
from low to high spin. Accompanying this spin state change is
FIG. 6. Michaelis-Menten curve for
the NADPH-dependent O-dealkyla-
tion of 7-ethoxycoumarin catalyzed
by P450 RhF. NADPH was used as the
electron donor.
FIG. 7. Inhibitor studies of P450 RhF. Michaelis-Menten curves
(top) and the corresponding Lineweaver-Burk plots (bottom) of the
kinetics of O-dealkylation of 7-ethoxycoumarin in the absence ( -) or
presence of the inhibitor 1-phenylimidazole (E-E, 5 mM and f-f,
10 mM).
FIG. 8. Potentiometric titration of intact P450 RhF. The upper
panel shows visible absorption spectra of the key intermediate redox
states of the protein during the titration: hemeox:FMNox (thick solid
line), hemeox:FMNsq (thin solid line); hemeox:FMNred (thin hatched
line); hemered:FMNred (thick hatched line). Lower panel shows the var-
iation in absorbance with applied potential. Open circles correspond to
absorption changes primarily associated with the heme (A418 nm, right
axis), open-dot circles correspond to absorption changes primarily asso-
ciated with the FMN (A462 nm, left axis). The data are fitted simulta-
neously to two-electron Nernst equations as described under “Experi-
mental Procedures,” using Microcal Origin 7.
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a large positive shift in reduction potential of around 130 mV
(16). This change is spin-state and potential is required for
efficient delivery of electrons from the reductase to the heme.
Clearly a similar change would be required for efficient elec-
tron transfer to the heme in P450 RhF. Unfortunately, to date,
binding trials with a variety of possible substrates have failed
to produce any significant perturbation of the spin state. This
lack of spin state change is probably the primary reason for the
poor turnover rates and low coupling seen with a substrate
such as 7-ethoxycoumarin.
Although the turnover of 7-ethoxycoumarin to 7-hydroxycou-
marin is quite low (about 5 mol of substrate turned over per 1
mol of P450 RhF per minute), the primary objective of this
study was to show self-sufficiency. Nevertheless, this single
polypeptide electron transfer route could well support high
catalytic activity. Indeed, the catalytic activity of P450 BM3 is
the highest determined for a P450 monooxygenase (17,000
min1 for arachidonate) (17). Such high activity is due in large
part to the highly efficient electron transfer from the NADPH
cofactor via the reductase to the P450 heme within a single
polpeptide chain (18, 19). The correlation between efficient
electron transfer housed on a single polypeptide and a high
level of substrate turnover, as observed for P450 BM3, is prob-
ably a general feature of this type of P450 enzyme.
The identity of the likely natural substrate(s) for P450 RhF
is currently unknown. Discovery of a natural substrate will
also help elucidate the physiological role of P450 RhF and
possibly its counterparts in other organisms. As pointed out by
De Mot and Parret (8) these enzymes are present in phyloge-
netically unrelated bacteria. It will be intriguing to determine
whether the function of the enzymes is conserved among these
diverse organisms.
In the well-characterized phthalate dioxygenase, the in-
tramolecular electrons flow from NADH to the semiquinone
FMN and then to the [2Fe-2S] redox cluster (20). The signifi-
cant degree of sequence homology between these reductases
and the C-terminal portion of P450 RhF suggests that they
possess, mutatis mutandis, a similar mechanism. We are cur-
rently dissecting the individual electron transfer steps by a
combination of stopped-flow studies involving intact P450 RhF
and mixed domain fragments. Fundamental studies into the
electron transfer mechanism will provide valuable information
concerning domain interactions for efficient electron transport
and catalysis in these enzymes.
Acknowledgments—We thank Hannah Florance (Institute of Cell
and Molecular Biology, University of Edinburgh) for assistance with the
MALDI-TOF analysis and Simon Daff (School of Chemistry, University
of Edinburgh) for useful discussions.
REFERENCES
1. Nerbert, D. W., and Gonzalez, F. J. (1987) Annu. Rev. Biochem. 56, 945–993
2. Narhi, L. O., and Fulco, A. J. (1986) J. Biol. Chem. 261, 7160–7169
3. Ravichandran, K. G., Boddupalli, S. S., Hasermann, C. A., Peterson, J. A., and
Deisenhofer, J. (1993) Science 261, 731–736
4. Kunst, F., Ogasawara, N., Moszer, I., Albertini, A. M., Alloni, G., Azevedo, V.,
Bertero, M. G., Bessieres, P., Bolotin, A., Borchert, S., Borriss, R., Boursier,
L., Brans, A., Braun, M., Brignell, S. C., Bron, S., Brouillet, S., Bruschi,
C. V., Caldwell, B., Capuano, V., Carter, N. M., Choi, S.-K., Codani, J.-J.,
Connerton, I. F., Cummings, N. J., Daniel, R. A., Denizot, F., Devine, K. M.,
Dusterhoft, A., Ehrlich, S. D., Emmerson, P. T., Entian, K. D., Errington, J.,
Fabret, C., Ferrari, E., Foulger, D., Fritz, C., Fujita, M., Fujita, Y., Fuma,
S., Galizzi, A., Galleron, N., Ghim, S.-Y., Glaser, P., Goffeau, A., Golightly,
E. J., Grandi, G., Guiseppi, G., Guy, B. J., Haga, K. et al. (1997) Nature 390,
249–256
5. Yu, T.-W., Bai, L., Clade, D., Hoffmann, D., Toelzer, S., Trinh, K. Q., Xu, J.,
Moss, S. J., Leistner, E., and Floss, H. G. (2002) Proc. Natl. Acad. Sci.
U. S. A. 99, 7968–7973
6. Kitazume, T., Takaya, N., Nakayama, N., and Shoun, H. (2000) J. Biol. Chem.
275, 39734–39740
7. Seo, J.-A., Proctor, R. H., and Plattner, R. D. (2001) Fungal Genet. Biol. 34,
155–165
8. De Mot, R., and Parret, A. H. A. (2002) Trends Microbiol. 10, 502–508
9. Roberts, G. A., Grogan, G., Greter, A., Flitsch, S. L., and Turner, N. J. (2002)
J. Bacteriol. 184, 3898–3908
10. Nagy, I., Schoofs, G., Compernolle, F., Proost, P., Vanderleyden, J., and De
Mot, R. (1995) J. Bacteriol. 177, 676–687
11. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY
12. Grogan, G., Roberts, G. A., Bougioukou, D., Turner, N. J., and Flitsch, S. L.
(2001) J. Biol. Chem. 276, 12565–12572
13. Omura, T., and Sato, R. (1964) J. Biol. Chem. 239, 2370–2378
14. Ortiz de Montellano, P. R. (1995) Cytochrome P450, Structure, Mechanism,
and Biochemistry, 2nd Ed., pp. 305–364, Plenum Publishing Corp., New
York
15. Daff, S. N., Chapman, S. K., Turner K. L., Holt, R. A., Govindaraj, S., Poulos,
T. L., and Munro, A. W. (1997) Biochemistry 36, 13816–13823
16. Ost, T. W. B., Miles, C. S., Munro, A. W., Murdoch, J., Reid, G. A., and
Chapman, S. K. (2001) Biochemistry 40, 13421–13429
17. Noble, M. A., Miles, C. S., Chapman, S. K., Lysek, D. A., MacKay, A. C., Reid,
G. A., Hanzlik, R. P., and Munro, A. W. (1999) Biochem. J. 339, 371–379
18. Munro, A. W., Leys, D. G., McLean, K. J., Marshall, K. R., Ost, T. W. B., Daff,
S., Miles, C. S., Chapman, S. K., Lysek, D. A., Moser, C. C., Page, C. C., and
Dutton, P. L. (2002) Trends Biochem. Sci. 27, 250–257
19. Munro, A. W., Daff, S., Coggins, J. R., Lindsay, J. G., and Chapman, S. K.
(1996) Eur. J. Biochem. 239, 403–409
20. Correll, C. C., Batie, C. J., Ballou, D. P., and Ludwig, M. L. (1992) Science 258,
1604–1610
Biochemical Characterization of P450 RhF48920
 at UQ Library on December 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Stephen K. Chapman, Nicholas J. Turner and Sabine L. Flitsch
Gareth A. Roberts, Ayhan Çelik, Dominic J. B. Hunter, Tobias W. B. Ost, John H. White,
Includes a Flavin Domain and a [2Fe-2S] Redox Center
A Self-sufficient Cytochrome P450 with a Primary Structural Organization That
doi: 10.1074/jbc.M309630200 originally published online September 27, 2003
2003, 278:48914-48920.J. Biol. Chem. 
  
 10.1074/jbc.M309630200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/278/49/48914.full.html#ref-list-1
This article cites 17 references, 9 of which can be accessed free at
 at UQ Library on December 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
